Coronavirus Notebook: UK OKs Moderna Vaccine For Younger People, New Study Says Pfizer & AZ Vaccines Effective Against Delta Variant
Two antibody products, one from ExeVir Bio, the other from Tiziana Life Sciences, have shown efficacy against COVID-19 in clinical trials.
You may also be interested in...
Coronavirus Notebook: ‘No Urgent Need’ For Booster Vaccines, But EU & UK Advise Additional Doses In Immunocompromised
ExeVir Bio has begun a Phase Ib study of its neutralizing antibody XVR011, NRx Pharmaceuticals has reported promising results with aviptadil in improving lung function, and Meletios Therapeutics has raised funds to further the development of an antiviral that acts on the SARS-CoV-2 virus and infected host cells.
Coronavirus Notebook: EU Agencies Update On ‘Mix-And-Match’ & Booster Vaccines, UK Expands Human Challenge Trial
ExeVir’s potential antibody therapy against variants of concern is moving into clinical trials, and Irish researchers say an abandoned glioblastoma candidate compound could prevent respiratory and cardiovascular damage in COVID-19 patients.
New recommendations could result in more effective prescribing and fewer adverse events.